The landmark PARADIGM-HF trial was the largest clinicaltrial ever conducted in heart failure1

Stopped early due to compelling efficacy: risk of CV death was significantlyreduced and the primary end point was met2

See this link for more info on Entresto:

https://www.entrestohcp.com/paradigm-hf-clinical-trial

I first heard about Entresto when I read a post on this board by Deke on 10-24-16.

The Phase III trial was the largest ever conducted on heart failure patients and the drug was fast tracked due to its compelling efficacy.

Last week I had my semiannual cardio evaluation at Penn Univ Hospital. After a discussion of my current condition and medications, my cardiologist prescribed Entresto for me. 

The reason I bring up Entresto on this board is that the major endpoint for the trial was to reduce mortality rates in patients with reduced ejection fractures (<35%). Patients in this category are prone to heart failure. Entresto is a combination small pill prescription (sacubitril/valsartan), administered orally. Interestingly enough, The drug is not recommended for patients with impaired or reduce kidney funtion - the RVX niche, therefore not a direct competitor. The therapy cost ~ $4,500 per year ~ double RVX. If RVX is on track to meet the trial endpoints and establishes compelling efficay, a 35% reduction of MACE events for diabetics would be well accepted by the medical community, and perhaps RVX may get fast tracked also.

jmo

Chicagoest